A recent study confirmed amoxicillin’s lower risk of treatment failure compared to penicillin V in treating pediatric pneumonia, with no difference in severe complications.
atai Life Sciences Announces Results from the Phase 1 IV-to-Subcutaneous Bridging Study of PCN-101 (R-Ketamine) | Psychedelic Invest
atai Life Sciences (NASDAQ: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, announced results from Perception Neuroscience’s Phase 1